- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about IBB
Recent news which mentions IBB
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
From Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
February 25, 2022
From Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
From Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
From Benzinga
Get Ready for a Biotech ETF Comeback
February 17, 2022
From ETF Trends
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
From Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
From Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
February 15, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
From Benzinga
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
February 11, 2022
From Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
From Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
February 09, 2022
From Benzinga
Biotech ETFs Muddled Despite Amgen Strength
February 08, 2022
From ETF Trends
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
From Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
From Benzinga
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
From Benzinga
Small-Cap Biotech Opportunity Knocks
February 01, 2022
From ETF Trends
CNBC's Final Trades: NXP Semiconductors, Qualcomm, Deere And This Way To Gain Exposure To Growth Potential
February 01, 2022
From Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.